These findings are confirmatory and verify results from previously published independent single-centre studies, which demonstrated the protective impact of IL-17A neutralization on stroke outcome.13,14,19 In the stroke field, our study is the third positive preclinical trial overall with an inflammatory target. The gene discussed is IL17A; the disease is Stroke.